Background {#Sec1}
==========

Articular cartilage is a highly specialised tissue acting as a shock absorber, enabling synovial joints to articulate with low frictional forces. Due to its avascular, aneural and alymphatic state, it has a limited repair potential \[[@CR1]\]. Surgical options to manage damaged articular cartilage include arthroscopic debridement \[[@CR2]--[@CR5]\], bone marrow stimulation techniques \[[@CR6]--[@CR8]\], chondrocyte implantation \[[@CR9]--[@CR13]\], osteochondral autografts (mosaicplasty) \[[@CR2], [@CR14], [@CR15]\], osteochondral allograft \[[@CR16]--[@CR18]\] and, in the presence of osteoarthritis, joint replacement \[[@CR19]\].

Bone marrow stimulation techniques, such as microfracture, are the most frequently used method in clinical practice for treating small symptomatic lesions of the articular cartilage \[[@CR6]--[@CR8]\]. However, the resulting tissue has shown to be a mixed fibrocartilage tissue \[[@CR20]--[@CR22]\] with varying amounts of type II collagen \[[@CR8], [@CR21], [@CR23], [@CR24]\] and inferior to native hyaline cartilage. Fibrocartilage is vulnerable to shear stresses and prone to breaking down over time \[[@CR20]\]. Subchondral osseous overgrowth has also been reported after microfracture \[[@CR25], [@CR26]\]. Osteochondral grafts can lead to donor site morbidity and healing seams at the recipient site \[[@CR27], [@CR28]\]. Autologous chondrocyte implantation (ACI) \[[@CR9], [@CR10]\] and its later evolution, matrix-induced autologous chondrocyte implantation (MACI), offered great promise with 80% of patients showing good or excellent results at 10 years \[[@CR29]\] but at best results in hyaline-like repair and has experienced complications such as graft failure, periosteal hypertrophy and delamination \[[@CR30], [@CR31]\]. In addition, it has also been reported that cells may lose their phenotype during expansion \[[@CR32], [@CR33]\].

There is therefore a growing interest in regenerative medicine, which can broadly be thought of as two main types: cell therapy, where cells are injected directly into the blood or into tissues, and tissue engineering, where cell-scaffold combinations are used to repair or regenerate tissues.

Stem cells are cells that have the ability to divide and develop into many different cell types in the body and can be categorised as pluripotent and multipotent. Pluripotent stem cells are often harvested from embryonic sources and can develop into any type of cell in the body whereas multipotent stem cells are generally taken from adults and can divide and develop into a more limited range of cell types. When stem cells divide, the new cells can either remain stem cells or develop into a new type of cell with a more specific function (Table [1](#Tab1){ref-type="table"}).Table 1Table describing the three main properties of stem cellsStem cell properties• They are unspecialized ("blank slates" that can become specific types of cells).• They can develop into specialized cell types (cells that do specific work in the body).• They are capable of surviving over long periods and divide to make additional stem cells.

Mesenchymal stem cells (MSCs) are a form of multipotent cells that may offer an alternative to cartilage repair techniques not hampered by availability and donor site morbidity.

The introduction of stem cell therapies into clinical practice however is a form of translational research, which as per any "bench-to-bedside" pathway now has enormous governance issues \[[@CR34], [@CR35]\] and is highly regulatory across four phases (Table [2](#Tab2){ref-type="table"}) and by the Tissues and Cells Directive (2004/23/EC) <https://www.hta.gov.uk/policies/eu-tissue-and-cells-directives>.Table 2Description of the different phases of clinical trialsClinical trial phases (http://www.nlm.nih.gov/services/ctphases.html)Phase I: Safety Studies or First-In-Man. Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.Phase II: Uncontrolled Efficacy Studies. The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.Phase III: Randomised Clinical Trials. The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.Phase IV: Post-Market Surveillance. Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Many published reviews on cartilage repair only list human clinical trials \[[@CR13], [@CR36]--[@CR46]\], underestimating the wealth of basic sciences and animal studies that are precursors to future research and may be relevant in clinical practice further down the line. In addition, true translation would imply that all of the clinical studies would have supporting pre-clinical data.

We therefore set out to perform a systematic review of the literature to assess the translation of stem cell therapy to explore what research had been carried out at each of the stages of translation from bench-top (in vitro)*,* animal (pre-clinical), and human studies (clinical) and assemble an evidence-based cascade for the responsible introduction of stem cell therapy for cartilage defects. In particular, we wanted to focus on the key burning questions pertaining to cartilage repair such as cell source, dosage (how many cells should be used), requirement for scaffolds and the role for extrinsic growth factors.

Main text {#Sec2}
=========

Search methodology {#Sec3}
------------------

This review was conducted in accordance to PRISMA guidelines \[[@CR47]\] using CINHAL, MEDLINE, EMBASE, Scopus and Web of Knowledge databases from 1st January 1900 to 30th June 2015.

The keywords used in the selection were "("mesenchymal stem cells"\[All Fields\] OR "mesenchymal stem cells"\[MeSH Terms\] OR "mesenchymal"\[All Fields\] OR "stem cells"\[All Fields\] OR "Stem Cells"\[MeSH Terms\] OR "MSC"\[All Fields\]) AND ("Articular Cartilage"\[MeSH Terms\] OR "articular"\[All Fields\] OR "cartilage"\[All Fields\] OR "cartilage"\[MeSH Terms\]) AND ("healing"\[All Terms\] OR "repair"\[All Terms\] OR "Regeneration"\[MeSH Terms\] OR "regeneration"\[All Fields\] OR "tissue engineering"\[MeSH Terms\] OR "tissue engineering"\[All Fields\]) AND ("defect"\[All Terms\]) AND ("chond\*"\[All Terms\])".

All review and non-English studies were excluded. For analysis, only original research studies were included. Any duplicates were excluded. Initially, KM and JS independently screened studies' title and abstract. Those included had the full text reviewed. Any disparities were discussed with the senior author (AJG). The references of eligible studies were also searched and included where relevant.

Unpublished trial databases (e.g. ClinicalTrials.gov) were reviewed as the grey literature using popular search engines, including Google. The keywords used for registered clinical trials in clinical trial databases were "stem cells", "cartilage" and "orthopaedics".

Eligible studies were drafted into tables tabulating the key data.

Results {#Sec4}
-------

The initial search identified 2880 study articles, of which 239 were included for analysis. The PRISMA flow diagram is shown in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Flow chart of literature search used for the review

### In vitro studies {#Sec5}

#### MSC source {#FPar1}

A list of cell sources used in the in vitro studies is shown in Table [3](#Tab3){ref-type="table"}. The commonest being human MSCs (66%) followed by rabbit MSCs (15%). The majority of the studies used bone marrow-derived MSCs (63%) followed by adipose tissue (33%). Two studies used commercial cell lines \[[@CR48], [@CR49]\].Table 3Cell species and cell sourcesCell speciesNo. of studiesReferencesCell SourceNo. of studies^a^ReferencesHuman73\[[@CR48], [@CR50], [@CR52], [@CR53], [@CR168]--[@CR236]\]Bone marrow62\[[@CR48], [@CR50]--[@CR53], [@CR164], [@CR168], [@CR170]--[@CR173], [@CR177]--[@CR180], [@CR182]--[@CR185], [@CR187], [@CR188], [@CR192], [@CR195]--[@CR197], [@CR203], [@CR206]--[@CR210], [@CR212], [@CR216], [@CR217], [@CR219], [@CR221], [@CR223], [@CR227], [@CR230], [@CR232]--[@CR235], [@CR237]--[@CR255]\]Rabbit17\[[@CR240]--[@CR242], [@CR246], [@CR249], [@CR252], [@CR255]--[@CR265]\]Adipose36\[[@CR66], [@CR169], [@CR175], [@CR176], [@CR181], [@CR186], [@CR189], [@CR193], [@CR194], [@CR199], [@CR201], [@CR202], [@CR211], [@CR214], [@CR216], [@CR218]--[@CR220], [@CR224], [@CR228], [@CR229], [@CR231], [@CR235], [@CR242], [@CR256], [@CR257], [@CR260]--[@CR269]\]Bovine5\[[@CR51], [@CR164], [@CR243], [@CR245], [@CR270]\]Synovium9\[[@CR174], [@CR191], [@CR200], [@CR213], [@CR222], [@CR226], [@CR258], [@CR259], [@CR270]\]Rat/mouse5\[[@CR239], [@CR250], [@CR266], [@CR269], [@CR271]\]Umbilical cord blood3\[[@CR205], [@CR236], [@CR190]\]Porcine3\[[@CR247], [@CR248], [@CR268]\]Commercial cell line2\[[@CR215], [@CR271]\]Equine3\[[@CR238], [@CR253], [@CR254]\]Placental2\[[@CR198], [@CR225]\]Goat1\[[@CR244]\]Embryonic1\[[@CR216]\]Ovine2\[[@CR237], [@CR251]\]Not stated0Not stated1\[[@CR267]\]^a^Some studies used cells from more than one cell source

#### Scaffold {#FPar2}

Within the in vitro studies, 26 different types of natural scaffold and 9 types of synthetic scaffolds were identified with a further 18 different types of hybrids, the most popular being a fibrin-polyurethane scaffold (Table [4](#Tab4){ref-type="table"}).Table 4Types of scaffoldsNumber of studies using types of scaffoldNaturalSyntheticHybridGrowth factor combinedNone used471422629ScaffoldNo. of studiesReferencesTypes of scaffolds usedNatural scaffolds Type I collagen hydrogel6\[[@CR185], [@CR190], [@CR211], [@CR226], [@CR241], [@CR251]\] Agarose hydrogel4\[[@CR53], [@CR247], [@CR248], [@CR268]\] Alginate bead3\[[@CR223], [@CR231], [@CR271]\] Fibrin hydrogel3\[[@CR208], [@CR211], [@CR263]\] Silk fibroin3\[[@CR198], [@CR216], [@CR256]\] Chitosan microspheres2\[[@CR260], [@CR262]\] Hyaluronic acid2\[[@CR195], [@CR237]\] Cartilage-derived matrix2\[[@CR193], [@CR238]\] K-carrageenan2\[[@CR169], [@CR199]\] Chitosan2\[[@CR168], [@CR216]\] Hyaluronic acid hydrogel2\[[@CR164], [@CR245]\] Gelatin-based scaffold2\[[@CR176], [@CR233]\] Devitalised cartilage ECM1\[[@CR220]\] Bead in bead alginate polysaccharide capsules1\[[@CR221]\] Atelocollagen gel1\[[@CR225]\] Fibrin disk1\[[@CR254]\] Methacrylated hyaluronic acid1\[[@CR164]\] Gelatin microspheres1\[[@CR260]\] Decellularised cell matrix1\[[@CR191]\] Collagen type I microspheres1\[[@CR52]\] Alginate microbeads1\[[@CR266]\] Alginate disks1\[[@CR270]\] Platelet rich plasma1\[[@CR242]\] Free oligosaccharide chondroitin sulphate C1\[[@CR205]\] Collagen type I sponge1\[[@CR237]\] 3D printed chitosan1\[[@CR181]\]Synthetic scaffolds Polycaprolactone3\[[@CR197], [@CR207], [@CR209]\] PLGA3\[[@CR194], [@CR204], [@CR257]\] Polylactic acid2\[[@CR230], [@CR232]\] PVA1\[[@CR244]\] PGA1\[[@CR178]\] Poly-DL-lactide-co-glycolide1\[[@CR194]\] Polylactide-co-caprolactone1\[[@CR214]\] GFOGER modified PEG hydrogel1\[[@CR183]\] OPF hydrogel1\[[@CR240]\]Hybrid scaffolds Fibrin--polurethane hydrogel4\[[@CR50], [@CR188], [@CR192], [@CR267]\] Esterified hyaluronan and gelatin polymer2\[[@CR212], [@CR255]\] TruFit CB (PLGA, calcium sulphate and polycolide)1\[[@CR187]\] PCL--HA bilayer1\[[@CR243]\] PEGDG--crosslinked hyaluronic acid1\[[@CR202]\] Polylactic acid--alginate1\[[@CR232]\] Sodium alginate--hyaluronic acid1\[[@CR189]\] Chitosan--collagen type I1\[[@CR258]\] Polyvinylalcohol--polycaprolactone1\[[@CR246]\] Tricalcium phosphate-collagen-hyaluronan1\[[@CR180]\] Poly-L-lactic acid--hydroxyapatite1\[[@CR215]\] Collagen type I--polylactic acid1\[[@CR217]\] Polylactic acid--polyglycolic acid with fibrin1\[[@CR261]\] Collagen--polyglycolic acid1\[[@CR252]\] Chondroitin sulphate C--collagen type II1\[[@CR236]\] Fibrin hydrogel with chondroitin sulphate1\[[@CR263]\] Chitosan-demineralised bone matrix1\[[@CR239]\] Alginate foam-chondroitin sulphate1\[[@CR170]\]Growth factor combined with scaffolds TGF-β1-loaded microspheres with chitosan microspheres1\[[@CR262]\] TGF-β1 releasing chitosan-collagen hydrogel1\[[@CR174]\] PEOT/PBT TGF-β1 loaded scaffolds1\[[@CR173]\] TGF-β1-activated chitosan/gelatin1\[[@CR249]\] PLGA nanospheres with TGF-β11\[[@CR172]\] TGF-β1 loaded Gelatin Microspheres1\[[@CR175]\]

#### Growth factors {#FPar3}

The commonest used growth factors were TGF-β and the bone morphogenetic protein (BMP) family. A list of growth factors used can be seen in Table [5](#Tab5){ref-type="table"}.Table 5Number of in vitro studies using different growth factorsGrowth factorNo. of studies (%)ReferencesGrowth factorNo. of studies (%)ReferencesTGF-β148 (44%)\[[@CR50], [@CR169]--[@CR175], [@CR189], [@CR190], [@CR192], [@CR193], [@CR195], [@CR199], [@CR202], [@CR208], [@CR210], [@CR211], [@CR213], [@CR214], [@CR216], [@CR217], [@CR220], [@CR222]--[@CR224], [@CR228], [@CR230]--[@CR232], [@CR234], [@CR235], [@CR244], [@CR246], [@CR249], [@CR252]--[@CR256], [@CR258], [@CR260]--[@CR263], [@CR266], [@CR267], [@CR270]\]SOX-51 (1%)\[[@CR204]\]TGF-β332 (29%)\[[@CR51], [@CR162], [@CR164], [@CR168], [@CR177], [@CR181]--[@CR184], [@CR197], [@CR200], [@CR205]--[@CR207], [@CR218], [@CR223]--[@CR225], [@CR227], [@CR237], [@CR239], [@CR240], [@CR245], [@CR247], [@CR248], [@CR250], [@CR251], [@CR257], [@CR259], [@CR267], [@CR268], [@CR270]\]SOX-61 (1%)\[[@CR204]\]BMP-213 (12%)\[[@CR188], [@CR202], [@CR213], [@CR219], [@CR225]--[@CR227], [@CR229], [@CR264], [@CR265], [@CR267], [@CR270], [@CR271]\]WNT3A1 (1%)\[[@CR171]\]FGF9 (8%)\[[@CR171], [@CR183], [@CR193], [@CR197], [@CR198], [@CR213], [@CR225], [@CR246], [@CR258]\]IL-11 (1%)\[[@CR197]\]IGF-17 (6%)\[[@CR179], [@CR184], [@CR192], [@CR213], [@CR224], [@CR254], [@CR265]\]EGF1(1%)\[[@CR193]\]BMP-67 (6%)\[[@CR181], [@CR216], [@CR219], [@CR224], [@CR227], [@CR250], [@CR266]\]OP-11 (1%)\[[@CR222]\]TGF-β24 (4%)\[[@CR209], [@CR219], [@CR238], [@CR270]\]AA2P1 (1%)\[[@CR266]\]GDF-53 (3%\[\[[@CR48], [@CR186], [@CR269]\]IL-101 (1%)\[[@CR178]\]SOX-92 (2%)\[[@CR204], [@CR221]\]TNFα1 (1%)\[[@CR178]\]BMP-42 (2%)\[[@CR227], [@CR271]\]PRP1 (1%)\[[@CR242]\]DEX2 (2%)\[[@CR224], [@CR266]\]IWP21 (1%)\[[@CR171]\]BMP-71 (1%)\[[@CR219]\]None15 (14%)\[[@CR52], [@CR176], [@CR180], [@CR185], [@CR187], [@CR191], [@CR194], [@CR196], [@CR201], [@CR212], [@CR215], [@CR233], [@CR236], [@CR241], [@CR243]\]PDGF1 (1%)\[[@CR202]\]

#### Cell seeding and passage {#FPar4}

There was wide heterogeneity in cell seeding density and there appeared to be no standard form of measurement. Li et al. \[[@CR50]\] examined three different seeding densities: 2, 5 and 10 × 10^6^ cells/scaffold, and found that scaffolds seeded with 5 × 10^6^ cells per scaffold induced the highest chondrogenesis; however, other groups \[[@CR51]--[@CR53]\] found that a higher seeding density results in better chondrogenesis.

Apart from 26 studies which did not state cell passage number, most studies used MSC of an early passage, anything between uncultured fresh (passage zero (P0) and five times passaged cells (P5). One study used cells of P6 \[[@CR54]\], and another study used cells between P4 and P7 \[[@CR48]\]. No relationship was apparent between chondrogenesis and number of passages.

#### Length of study {#FPar5}

The length of each in vitro study can be seen in Table [6](#Tab6){ref-type="table"}. The majority of studies were short-term models; 27 studies (25%) ended between 1 and 2 weeks, 35 studies (33%) ended between 2 and 3 weeks and 15 studies (14%) ended between 3 and 4 weeks.Table 6Length of studiesLength of studyNo. of studiesReferencesUp to 1 week9\[[@CR172], [@CR203], [@CR210], [@CR212], [@CR224], [@CR229], [@CR239], [@CR266], [@CR270]\]1--2 weeks27\[[@CR50], [@CR170], [@CR174], [@CR178], [@CR182], [@CR189], [@CR192], [@CR194], [@CR198], [@CR202], [@CR215], [@CR218], [@CR220], [@CR223], [@CR228], [@CR234], [@CR235], [@CR237], [@CR240], [@CR249], [@CR254], [@CR260]--[@CR265]\]2--3 weeks36\[[@CR52], [@CR53], [@CR168], [@CR169], [@CR173], [@CR175], [@CR179], [@CR180], [@CR183]--[@CR186], [@CR190], [@CR191], [@CR195], [@CR196], [@CR199], [@CR200], [@CR204], [@CR205], [@CR209], [@CR213], [@CR217], [@CR225], [@CR226], [@CR230], [@CR232], [@CR233], [@CR236], [@CR246], [@CR250], [@CR256], [@CR258], [@CR269], [@CR271]\]3--4 weeks15\[[@CR51], [@CR176], [@CR181], [@CR188], [@CR193], [@CR201], [@CR211], [@CR216], [@CR219], [@CR221], [@CR241], [@CR251], [@CR253], [@CR255], [@CR257]\]4--5 weeks7\[[@CR171], [@CR177], [@CR206], [@CR214], [@CR231], [@CR259], [@CR267]\]5--6 weeks10\[[@CR48], [@CR187], [@CR208], [@CR222], [@CR238], [@CR244], [@CR247], [@CR248], [@CR252], [@CR268]\]6--7 weeks1\[[@CR207]\]7--8 weeks1\[[@CR197]\]8--9 weeks3\[[@CR164], [@CR243], [@CR245]\]Not stated1\[[@CR242]\]

#### Method of assessment {#FPar6}

A range of techniques was used to assess chondrogenesis within the in vitro studies. These techniques consisted of histology, immunohistochemistry, qPCR, biochemical analysis, imagery and mechanical testing. The techniques used are summarised in Table [7](#Tab7){ref-type="table"}.Table 7Types of techniques used to assess chondrogenesis of MSCsType of techniquesNo. of studies (%)ReferencesHistology87 (79%)\[[@CR48], [@CR50]--[@CR53], [@CR164], [@CR168]--[@CR170], [@CR173]--[@CR175], [@CR177]--[@CR179], [@CR181]--[@CR187], [@CR191]--[@CR195], [@CR197]--[@CR201], [@CR204]--[@CR211], [@CR213]--[@CR217], [@CR219]--[@CR222], [@CR226], [@CR229], [@CR230], [@CR232]--[@CR238], [@CR240]--[@CR248], [@CR250], [@CR252]--[@CR264], [@CR267]--[@CR271]\]Immunohistochemistry78 (71%)\[[@CR48], [@CR50], [@CR52], [@CR53], [@CR168]--[@CR171], [@CR173]--[@CR175], [@CR178]--[@CR183], [@CR185]--[@CR191], [@CR193], [@CR194], [@CR197], [@CR198], [@CR201], [@CR203]--[@CR205], [@CR207], [@CR212]--[@CR215], [@CR217], [@CR218], [@CR220], [@CR221], [@CR224], [@CR226], [@CR228]--[@CR238], [@CR241], [@CR242], [@CR244], [@CR246]--[@CR248], [@CR250]--[@CR259], [@CR264], [@CR265], [@CR267]--[@CR271]\]qPCR70 (64%)\[[@CR53], [@CR168], [@CR169], [@CR173], [@CR174], [@CR176], [@CR178]--[@CR186], [@CR188], [@CR190], [@CR192]--[@CR194], [@CR196], [@CR199], [@CR200], [@CR202]--[@CR205], [@CR207]--[@CR209], [@CR211], [@CR214], [@CR216]--[@CR220], [@CR222]--[@CR232], [@CR235], [@CR236], [@CR239], [@CR240], [@CR242], [@CR246], [@CR249]--[@CR251], [@CR256], [@CR258], [@CR259], [@CR261]--[@CR263], [@CR265]--[@CR267], [@CR269]--[@CR271]\]Biochemical analysis64 (58%)\[[@CR48], [@CR50]--[@CR52], [@CR164], [@CR168], [@CR170]--[@CR172], [@CR176], [@CR177], [@CR179], [@CR180], [@CR182]--[@CR184], [@CR188], [@CR189], [@CR191], [@CR192], [@CR197], [@CR199], [@CR200], [@CR202], [@CR204], [@CR205], [@CR209], [@CR212], [@CR214], [@CR216]--[@CR219], [@CR222]--[@CR224], [@CR226], [@CR227], [@CR233]--[@CR240], [@CR244], [@CR245], [@CR247]--[@CR249], [@CR252], [@CR254], [@CR257], [@CR260]--[@CR266], [@CR268]--[@CR270]\]Imaging (confocal, SEM, TEM)24 (22%)\[[@CR52], [@CR172], [@CR176], [@CR180], [@CR185], [@CR187], [@CR194], [@CR198], [@CR208], [@CR215]--[@CR217], [@CR225], [@CR226], [@CR230], [@CR232], [@CR241], [@CR242], [@CR249], [@CR252], [@CR255], [@CR262], [@CR263], [@CR265]\]Mechanical testing15 (14%)\[[@CR51], [@CR52], [@CR164], [@CR169], [@CR175], [@CR193], [@CR197], [@CR207], [@CR220], [@CR245], [@CR247], [@CR248], [@CR256], [@CR257], [@CR268]\]

### Animal studies (pre-clinical) {#Sec6}

One hundred eleven animal studies were included of which 109 were controlled laboratory studies, one was a pilot study \[[@CR49]\] and one was a longitudinal case study on a race horse \[[@CR55]\]. The commonest animal studied with 59 studies was rabbit (53%). The different species of animals studied is shown in Table [8](#Tab8){ref-type="table"}.Table 8Different species of animals used to assess reparative effect of MSCs on cartilage defectAnimalsNo. of studies (%)ReferencesRabbits57 (51%)\[[@CR49], [@CR54]--[@CR102], [@CR134], [@CR150]--[@CR154], [@CR160], [@CR161], [@CR207], [@CR272]--[@CR324]\]Pigs16 (14%)\[[@CR61], [@CR62], [@CR68]--[@CR72], [@CR87], [@CR90], [@CR153], [@CR273], [@CR276], [@CR279], [@CR290], [@CR308]--[@CR310]\]Rats13 (12%)\[[@CR60], [@CR78]--[@CR82], [@CR91], [@CR152], [@CR160], [@CR278], [@CR286], [@CR311], [@CR312]\]Sheep8 (7%)\[[@CR89], [@CR272], [@CR282], [@CR283], [@CR313]--[@CR316]\]Goats5 (5%)\[[@CR49], [@CR95], [@CR100], [@CR101], [@CR318]\]Horses4 (4%)\[[@CR55], [@CR96], [@CR98], [@CR317]\]Dogs4 (4%)\[[@CR86], [@CR97], [@CR151], [@CR287]\]Monkeys2 (2%)\[[@CR319], [@CR320]\]Guinea pigs1 (\<1%)\[[@CR281]\]Donkeys1 (\<1%)\[[@CR57]\]

#### Defect {#FPar7}

The size of the defect varied from 2 to 25 mm^2^ in the smaller animals and from 1 to 64 mm^2^ in the larger animals. All but two studies \[[@CR56], [@CR57]\] used the knee for defect creation.

#### Stem cell type {#FPar8}

Bone marrow-derived stem cells were used in 84 studies (75%). Thirteen studies (11%) used adipose stem cells \[[@CR54], [@CR58]--[@CR69]\], six (5%) used synovia \[[@CR70]--[@CR75]\] and three (2%) used periostium-derived MSCs \[[@CR76]--[@CR78]\]. Three studies (3%) used embryonic stem cell-derived MSCs \[[@CR79]--[@CR81]\] whereas 2 studies (2%) used muscle-derived MSCs \[[@CR82], [@CR83]\]. One group showed promising results of allogenic MSCs in a rabbit model when compared to autologous cells, although numbers were small \[[@CR84], [@CR85]\]. Another used compared autologous chondroprogenitor cells and allogenic chondroprogenitor cells against controls in an equine model and reported that repair tissue quality in the allogenic cell group was not superior to that in the control (fibrin only) group and also showed poorer radiographic changes in the allogenic group \[[@CR23]\].

#### Cell culture, dose and delivery {#FPar9}

There was much variation in the number of cells implanted and the number of cell passages from 3--10 or more \[[@CR79], [@CR86]\].

The number of cells varied from 4 × 10^3^ -- 1 × 10^10^. The majority of studies used between 10^6^ and 10^8^ cells. Some did not specify the number of cells implanted. Two studies suggested that improved chondrogenesis occurs with a higher implanted cell number \[[@CR75], [@CR87]\], although others suggested that the high cell numbers increase the risk of synovitis \[[@CR75]\] and synovial proliferation \[[@CR88]\].

The cells were transplanted into the defect both as cell therapy (injection directly into the joint) (17 studies, 15%) or by tissue engineering (cell-scaffold combinations) (94 studies, 85%). Fifteen studies \[[@CR49], [@CR65], [@CR72], [@CR75], [@CR81], [@CR86], [@CR89]--[@CR97]\] used a mixture of solutions prepared from hyaluronic acid \[[@CR65], [@CR92], [@CR94]--[@CR97]\], phosphate buffer solution \[[@CR91]\], plasma \[[@CR75]\], basal medium with chondrogenesis \[[@CR89]\], collagen acid \[[@CR93]\], sodium alginate \[[@CR86]\] or a growth factor medium \[[@CR90]\]. Two studies used MSCs only \[[@CR49], [@CR72]\].

#### Scaffold {#FPar10}

Ninety-two studies (82%) used a scaffold. The material used was a synthetic polymer either collagen based, fibrinogen glue or a synthetic protein (e.g. rHuBMP-2) in 62 (56%) studies (Table [9](#Tab9){ref-type="table"}).Table 9Table showing the types of scaffold used in animal studiesScaffold typeNo. of studiesReferencesNo Scaffold19 (17%)\[[@CR49], [@CR54], [@CR61], [@CR70], [@CR72]--[@CR75], [@CR81], [@CR86], [@CR89]--[@CR91], [@CR97], [@CR100], [@CR102], [@CR280]--[@CR282], [@CR284]\]Poly (lactide-co-glycoside) PLGA17 (16%)\[[@CR56], [@CR59], [@CR62], [@CR63], [@CR83], [@CR88], [@CR150], [@CR153], [@CR160], [@CR277], [@CR285], [@CR286], [@CR289]--[@CR292], [@CR316]\]Fibrin/Fribrin glue11 (9%)\[[@CR55], [@CR64], [@CR76]--[@CR78], [@CR152], [@CR278], [@CR293], [@CR308], [@CR317], [@CR318]\]Hydrogel9 (8%)\[[@CR65], [@CR69], [@CR81], [@CR94], [@CR279], [@CR288], [@CR314], [@CR321], [@CR323]\]Collagen9 (8%)\[[@CR79], [@CR80], [@CR134], [@CR276], [@CR299], [@CR301], [@CR309], [@CR320], [@CR322]\]Hyaluronic acid7 (6%)\[[@CR57], [@CR92], [@CR95], [@CR96], [@CR273], [@CR304], [@CR324]\]Alginate beads4 (3%)\[[@CR65], [@CR84], [@CR101], [@CR294]\]Tissue membrane4 (3%)\[[@CR82], [@CR98], [@CR303], [@CR305]\]Polyglycolic acid3 (3%)\[[@CR99], [@CR161], [@CR274]\]PGA/PLA3 (3%)\[[@CR68], [@CR290], [@CR296]\]Hylauronan crosslinked matrix2 (2%)\[[@CR154], [@CR297]\]Poly-L-lactide-co-caprolactone2 (2%)\[[@CR275], [@CR300]\]Polycaprolactone cartilage (PCL)2 (2%)\[[@CR87], [@CR272]\]Animal-origin osteochondral plug scaffold2 (2%)\[[@CR272], [@CR298]\]Chitosan microspheres and fibrin glue1 (\<1%)\[[@CR60]\]Gel carries (collagen/HA/Fibrogen)1 (\<1%)\[[@CR71]\]Polychoxanone/poly(vinyl alcholo) PDO/PVA1 (\<1%)\[[@CR302]\]Cartilage aggregate1 (\<1%)\[[@CR306]\]Collagen/glycosaminoglycan porous titanium biphasic scaffold1 (\<1%)\[[@CR151]\]Articular chondrocyte seeded matrix associated autologous chondrocyte transplant (MACT)1 (\<1%)\[[@CR313]\]MSC-ADM (accellulo-dermal matrix)1 (\<1%)\[[@CR319]\]Hyaff-11 scaffold1 (\<1%)\[[@CR295]\]Porous-gelatin-chonroitin hyaluronate1 (\<1%)\[[@CR291]\]Bone protein 7 PCL1 (\<1%)\[[@CR66]\]Human acellular amniotic membrane1 (\<1%)\[[@CR307]\]Pluronic-F 1271 (\<1%)\[[@CR102]\]Tricalcium phosphate1 (\<1%)\[[@CR315]\]Agarose1 (\<1%)\[[@CR311]\]GCH-GCBB1 (\<1%)\[[@CR93]\]ACHMS (atelocollagen honeycomb-shaped membrane)1 (\<1%)\[[@CR58]\]Magnet1 (\<1%)\[[@CR310]\]Human cartilage extra cellular matrix 3D porous acellular1 (\<1%)\[[@CR67]\]

#### Growth factors {#FPar11}

Thirty-two studies (29%) assessed the effect of growth factors on MSC chondrogenesis. Seventeen out of 38 (44%) used TGF-β1/3 (Table [10](#Tab10){ref-type="table"}), the majority of which show a positive effect on chondrogenesis.Table 10Table showing growth factors used in animal studiesGrowth factorNo. of studiesReferencesTGF-β3/1/217 (15%)\[[@CR56], [@CR65], [@CR66], [@CR70], [@CR76], [@CR85], [@CR90], [@CR100], [@CR280], [@CR282], [@CR285], [@CR287], [@CR290], [@CR291], [@CR309], [@CR311], [@CR323]\]CDMP--12 (2%)\[[@CR56], [@CR134]\]FGF-22 (2%)\[[@CR90], [@CR304]\]Ad-hTGF-B11 (\<1%)\[[@CR321]\]AdBMP--21 (\<1%)\[[@CR78]\]chABC1 (\<1%)\[[@CR74]\]PRP1 (\<1%)\[[@CR75]\]Gene modified MSCs (gene modification to BcL-xL gene)1 (\<1%)\[[@CR299]\]hiGF-1-DNA1 (\<1%)\[[@CR101]\]AdIGF--11 (\<1%)\[[@CR78]\]rHuBMP--21 (\<1%)\[[@CR82]\]Ham-F-121 (\<1%)\[[@CR303]\]NaO111 (\<1%)\[[@CR277]\]NSC23766-Rac1 inhibitor1 (\<1%)\[[@CR60]\]

#### Associated procedures {#FPar12}

Ten of the studies compared MSC treatment against other surgical modalities such as debridement \[[@CR55]\], microfracture \[[@CR49], [@CR91], [@CR96], [@CR98], [@CR99]\] and mosaicplasty \[[@CR77], [@CR100]--[@CR102]\].

#### Outcome measures {#FPar13}

There were a variety of outcome measures used to analyse the results of the studies. The majority of studies (79%) used evidence of hyaline-like cartilage as being a positive outcome (Tables [11](#Tab11){ref-type="table"} and [12](#Tab12){ref-type="table"}).Table 11Outcome measures used in animal studies (some studies used more than one outcome measure)Outcome scoreNo. of studies using the score (%)ReferencesHistology scores111 (100%)\[[@CR49], [@CR54]--[@CR102], [@CR134], [@CR150]--[@CR154], [@CR160], [@CR161], [@CR272]--[@CR324]\]International Cartilage Repair Society Score26 (23%)\[[@CR49], [@CR60], [@CR61], [@CR63], [@CR66], [@CR69], [@CR72], [@CR74], [@CR79], [@CR89], [@CR92], [@CR94], [@CR98], [@CR99], [@CR272], [@CR282], [@CR283], [@CR289], [@CR305], [@CR306], [@CR310], [@CR313], [@CR314], [@CR316], [@CR319], [@CR324]\]Wakitani score21 (19%)\[[@CR58], [@CR62], [@CR67], [@CR68], [@CR72], [@CR73], [@CR80], [@CR82], [@CR97], [@CR151], [@CR273], [@CR277], [@CR279], [@CR284], [@CR285], [@CR290], [@CR299], [@CR304], [@CR310], [@CR321]\]O'Driscoll score2018%\[[@CR49], [@CR71], [@CR81], [@CR84], [@CR85], [@CR93], [@CR100], [@CR160], [@CR272], [@CR276], [@CR290], [@CR296]--[@CR298], [@CR302], [@CR306], [@CR308], [@CR313], [@CR314], [@CR322]\]Functional scores/mechanical11 (10%)\[[@CR55], [@CR57], [@CR62], [@CR67], [@CR69], [@CR81], [@CR101], [@CR277], [@CR287], [@CR290], [@CR315]\]MRI scores5 (5%)\[[@CR63], [@CR69], [@CR96], [@CR101], [@CR316]\]Arthroscopy scores5 (5%)\[[@CR72], [@CR96], [@CR310], [@CR317], [@CR318]\]Macroscopic osteoarthritis score3 (3%)\[[@CR57], [@CR281], [@CR295]\]Pineda score3 (3%)\[[@CR290], [@CR293], [@CR309]\]Schreiber score2 (2%)\[[@CR101], [@CR300]\]Britternberg score2 (2%)\[[@CR84], [@CR85]\]Slochagg score1 (\<1%)\[[@CR300]\]Moran score1 (\<1%)\[[@CR64]\]Gill score1 (\<1%)\[[@CR95]\] Table 12Analysis technique used on repaired tissueAnalysis usedNo. of studies (%)ReferencesHyaline-like cartilage88 (79%)\[[@CR49], [@CR54]--[@CR56], [@CR58], [@CR59], [@CR61], [@CR62], [@CR64]--[@CR69], [@CR71]--[@CR73], [@CR75], [@CR76], [@CR78]--[@CR89], [@CR92], [@CR95], [@CR97], [@CR98], [@CR100], [@CR101], [@CR134], [@CR150]--[@CR152], [@CR154], [@CR160], [@CR161], [@CR273]--[@CR280], [@CR285]--[@CR302], [@CR304], [@CR305], [@CR307], [@CR309], [@CR310], [@CR312], [@CR314]--[@CR324]\]Collagen type II84 (76%)\[[@CR54], [@CR56]--[@CR59], [@CR62], [@CR65]--[@CR73], [@CR75]--[@CR88], [@CR90], [@CR91], [@CR93]--[@CR96], [@CR98], [@CR100]--[@CR102], [@CR134], [@CR150]--[@CR154], [@CR160], [@CR161], [@CR272]--[@CR276], [@CR278]--[@CR282], [@CR284]--[@CR288], [@CR292], [@CR294]--[@CR296], [@CR300], [@CR302]--[@CR306], [@CR308], [@CR309], [@CR311], [@CR313]--[@CR315], [@CR317]--[@CR319], [@CR321], [@CR323]\]Cluster Chondrocytes34 (31%)\[[@CR57], [@CR60], [@CR62], [@CR63], [@CR72], [@CR74], [@CR77], [@CR78], [@CR80], [@CR81], [@CR83], [@CR84], [@CR91], [@CR97], [@CR102], [@CR151], [@CR152], [@CR160], [@CR161], [@CR273], [@CR276], [@CR280], [@CR281], [@CR283], [@CR291], [@CR292], [@CR296], [@CR297], [@CR304], [@CR312], [@CR318], [@CR319], [@CR322], [@CR324]\]Glycosaminoglycan40 (36%)\[[@CR49], [@CR62], [@CR65], [@CR67]--[@CR71], [@CR73]--[@CR75], [@CR81], [@CR85], [@CR87], [@CR94], [@CR96]--[@CR101], [@CR160], [@CR272], [@CR274], [@CR279], [@CR282], [@CR286], [@CR288], [@CR290], [@CR291], [@CR296], [@CR300], [@CR301], [@CR308], [@CR309], [@CR311], [@CR312], [@CR315], [@CR319], [@CR323]\]Genes22 (20%)\[[@CR56], [@CR60], [@CR61], [@CR63], [@CR64], [@CR66], [@CR78], [@CR80], [@CR82], [@CR90], [@CR94], [@CR96], [@CR134], [@CR275], [@CR277], [@CR283], [@CR285], [@CR294], [@CR311], [@CR316], [@CR321], [@CR323]\]Proteoglycan8 (7%)\[[@CR56], [@CR63], [@CR84], [@CR95], [@CR98], [@CR287], [@CR294], [@CR295]\]

### Human studies (clinical) {#Sec7}

Thirty-one published studies by 15 different groups looked at clinical applications of MSCs. One used allogenic stem cells \[[@CR103]\] and the rest autologous stem cells. The types of studies can be seen in Tables [13](#Tab13){ref-type="table"} and [14](#Tab14){ref-type="table"}.Table 13Number of publications for each study type and phaseCategoryNo. of studies (total 28)ReferencesPhases of clinical studies Pilot/feasibility study incl. case report15 (54%)\[[@CR104]--[@CR108], [@CR118], [@CR119], [@CR122], [@CR124]--[@CR129], [@CR133]\] Phase 1 (safety assessment)8 (26%)\[[@CR109]--[@CR112], [@CR116], [@CR123], [@CR130], [@CR131]\] Phase 2 (efficacy assessment)8 (26%)\[[@CR103], [@CR113]--[@CR115], [@CR117], [@CR120], [@CR121], [@CR132]\] Phase 3 (large scale efficacy assessment through a multi-centre RCT)0 (0%)-- Phase 4 (post-market surveillance)0 (0%)-- Table 14Summary of the published clinical studiesCategoryNo. of studiesReferencesCell source Bone marrow22 (71%)\[[@CR103]--[@CR105], [@CR109], [@CR111]--[@CR113], [@CR115]--[@CR118], [@CR120], [@CR122]--[@CR128], [@CR130]--[@CR132]\] Adipose5 (16%)\[[@CR106]--[@CR108], [@CR110], [@CR114]\] Peripheral blood2 (6%)\[[@CR119], [@CR121]\] Synovium2 (6%)\[[@CR129], [@CR133]\]Cell delivery Arthroscopic implantation  Hyaluronic acid membrane2 (6%)\[[@CR117], [@CR130]\]  Hyaluronic acid with fibrin glue or platelet gel2 (6%)\[[@CR116], [@CR128]\]  Polyglycolic acid/hyaluronan2 (6%)\[[@CR127], [@CR131]\]  Collagen with platelet gel1 (3%)\[[@CR116]\]  Fibrin glue1 (3%)\[[@CR108]\]  HYAFF 11 scaffold1 (3%)\[[@CR132]\]  Acetate Ringer solution1 (3%)\[[@CR133]\]  Unspecified1 (3%)\[[@CR107]\]Intra-articular injection  PBS only2 (6%)\[[@CR104], [@CR110]\]  PBS with HA2 (6%)\[[@CR119], [@CR121]\]  Autologous serum2 (6%)\[[@CR115], [@CR123]\]  Ringer lactate solution3 (10%)\[[@CR103], [@CR111], [@CR112]\]  PBS with serum albumin1 (3%)\[[@CR105]\]  HA and PRP1 (3%)\[[@CR106]\]  PRP1 (3%)\[[@CR114]\]  Commercial serum1 (3%)\[[@CR109]\]Transplantation by open surgery  Collagen6 (21%)\[[@CR103], [@CR113], [@CR118], [@CR122], [@CR124], [@CR126], [@CR129]\]  Ascorbic acid-mediated sheet2 (7%)\[[@CR120], [@CR123]\]  Fibrin glue1 (4%)\[[@CR125]\]Cell dose Less than 10 million8 (26%)\[[@CR105], [@CR107], [@CR108], [@CR114], [@CR120], [@CR122], [@CR124], [@CR129]\] 10--20 million5 (16%)\[[@CR113], [@CR118], [@CR119], [@CR123], [@CR125]\] Over 20 million7 (23%)\[[@CR103], [@CR104], [@CR109]--[@CR112], [@CR133]\] Unspecified11 (35%)\[[@CR106], [@CR115]--[@CR117], [@CR121], [@CR126]--[@CR128], [@CR130]--[@CR132]\]Follow-up Up to 6 months4 (13%)\[[@CR104]--[@CR106], [@CR110]\] Up to 12 months6 (19%)\[[@CR103], [@CR109], [@CR111], [@CR124], [@CR125], [@CR127]\] Up to 2 years11 (35%)\[[@CR107], [@CR113]--[@CR116], [@CR120], [@CR121], [@CR128]--[@CR131]\] Up to 3 years7 (23%)\[[@CR108], [@CR112], [@CR117], [@CR119], [@CR122], [@CR126], [@CR132]\] Over 3 years2 (6%)\[[@CR118], [@CR133]\]Assessments Radiology (MRI, X-ray)24 (77%)\[[@CR103]--[@CR106], [@CR109]--[@CR112], [@CR115]--[@CR117], [@CR119], [@CR121]--[@CR125], [@CR127]--[@CR133]\] Arthroscopic assessment incl. histology17 (54%)\[[@CR107], [@CR108], [@CR113], [@CR116]--[@CR122], [@CR124]--[@CR126], [@CR130]--[@CR133]\] IKDC10 (32%)\[[@CR107], [@CR108], [@CR115], [@CR121], [@CR122], [@CR126], [@CR128], [@CR130]--[@CR132]\] VAS pain12 (39%)\[[@CR103]--[@CR106], [@CR109]--[@CR112], [@CR114], [@CR129], [@CR131], [@CR132]\] Tegner activity scale8 (26%)\[[@CR107], [@CR108], [@CR114], [@CR115], [@CR129], [@CR131]--[@CR133]\] Lysholm6 (19%)\[[@CR114], [@CR115], [@CR125], [@CR128], [@CR131], [@CR133]\] KOOS5 (16%)\[[@CR126], [@CR128]--[@CR130], [@CR132]\] Function (no scoring systems or unspecified)4 (13%)\[[@CR104]--[@CR106], [@CR109]\] ICRS cartilage injury evaluation package3 (10%)\[[@CR120], [@CR123], [@CR125]\] Clinical symptoms/outcomes (no scoring system or unspecified)3 (10%)\[[@CR105], [@CR109], [@CR124]\] (Revised) Hospital for special surgery knee-rating scale2 (6%)\[[@CR113], [@CR125]\] Functional Rating Index2 (6%)\[[@CR104], [@CR106]\] WOMAC5 (16%)\[[@CR103], [@CR109]--[@CR112]\] AOFAS score2 (6%)\[[@CR112], [@CR116], [@CR117]\] Knee Society Score1 (3%)\[[@CR110]\] Harris Hip Score1 (3%)\[[@CR112]\]Concomitant procedures Subchondral bone marrow stimulation (multiple perforation, drilling, abrasion chondroplasty)11 (35%)\[[@CR113], [@CR115], [@CR118], [@CR119], [@CR121]--[@CR123], [@CR125], [@CR127], [@CR128], [@CR131]\] Debridement, synovectomy, excision of degenerative tears (no subchondral bone marrow stimulation)8 (26%)\[[@CR107], [@CR108], [@CR114], [@CR116], [@CR117], [@CR124], [@CR130], [@CR133]\] ACL reconstruction, meniscus repair, osteotomy, or patella alignment, ACL calcification removal, trochlear resurfacing, osteochondral fragment fixation8 (26%)\[[@CR115], [@CR123], [@CR126], [@CR129]--[@CR133]\] None6 (19%)\[[@CR103], [@CR105], [@CR106], [@CR110]--[@CR112]\] Not specified3 (10%)\[[@CR104], [@CR109], [@CR120]\]Previous procedures Microfractures/multiple perforation/multiple drilling6 (19%)\[[@CR104], [@CR116], [@CR117], [@CR122], [@CR125], [@CR130]\] Menisectomy6 (19%)\[[@CR103], [@CR111], [@CR124], [@CR129], [@CR131], [@CR133]\] ACL reconstruction4 (13%)\[[@CR103], [@CR111], [@CR131], [@CR133]\] Multiple (microfracture, debridement)1 (3%)\[[@CR119]\] ACI2 (6%)\[[@CR116], [@CR117]\] None6 (19%)\[[@CR106]--[@CR108], [@CR110], [@CR114], [@CR118]\] Not specified9 (29%)\[[@CR105], [@CR109], [@CR112], [@CR115], [@CR120], [@CR121], [@CR126], [@CR128], [@CR132]\]*PBS* phosphate-buffered saline, *HA* hyaluronic acid, *PRP* plate-rich-plasma, *RCT* randomised controlled study, *KOOS* Knee and Osteoarthritis Outcome Score, *IKDC score* International Knee Documentation Committee Score, *WOMAC* the Western Ontario and McMaster Universities Arthritis Index, *AOFAS* the American Orthopaedic Foot & Ankle Society

There were 52 unpublished clinical trials, majority of which are early phase studies (I--II; 63%) and only 5 trials were phase II/III. Table [15](#Tab15){ref-type="table"} shows a summary of these clinical trials.Table 15Clinical trials (unpublished/on-going) registered in ClinicalTrials.govTitleCell sourceCountryClinical trial phaseConditionStudy designEnrolmentFollow-upArm(s)Cell deliveryPrimary outcomesStudy status (on 8.3.2016)ClinicalTrials.gov IdentifierAutologous cellsMesenchymal Stem Cells in Knee Cartilage InjuriesBone marrowJordanIIAdvanced knee articular cartilage injuryNon-randomized parallel assignment; double blind1312 monthsCulture expanded MSCs alone vs. MSC with platelet lysateIntra-articular injectionTherapeutic benefitCompleted in August 2015; no publication foundNCT02118519Adult Stem Cell Therapy for Repairing Articular Cartilage in GonarthrosisBone marrowSpainI/IIGonarthrosis grade 2--3Open label; single group assignment1512 monthsCulture expanded MSCs (40 million cells)Articular injectionFeasibility/safetyCompleted in January 2013; no publication foundNCT01227694Autologous Bone Marrow Mesenchymal Stem Cells Transplantation for Articular Cartilage Defects RepairBone marrowUKI/IIKnee articular cartilage defectsRandomized parallel assignment; double blind1012 monthsMSCs (fresh or cultured unspecified)Intra-articular injectionChange in WOMACUnknown\
(estimated study completion date; July 2014)NCT01895413Mesenchymal Stem Cell for Osteonecrosis of the Femoral HeadBone marrowChina0Osteochondritis of the femoral headOpen label single group assignment155 yearsCulture expanded MSC and bone marrow nuclear cellsInfusion through medial femoral circumflex artery, lateral femoral circumflex artery and obturator arteryFemoral head blood-supply artery angiographies; femoral head necrosisUnknown\
(estimated study completion date; August 2015)NCT00813267The Effects of Intra-articular Injection of Mesenchymal Stem Cells in Knee Joint OsteoarthritisBone marrowIranIIKnee joint osteoarthritisSingle centre, randomised, placebo controlled, double blind403 monthsCulture-expanded MSCs vs. placeboIntra-articular injectionChanges in WOMAC physical function and VAS painCompleted in November 2012; no publication foundNCT01504464Safety and Efficacy of Autologous Bone Marrow Stem Cells for Treating OsteoarthritisBone marrowIndiaI/IIKnee OA Kellgren and Lawrence classification 3--4Open label single group assignment; multi-centre101 yearMSCs (fresh or culture-expanded unspecified)UnknownWOMAC pain score and safetyOn-going\
(estimated study completion date; January 2012)NCT01152125Treatment of Knee Osteoarthritis by Intra-articular Injection of Bone Marrow Mesenchymal Stem CellsBone marrowSpainI/IIKnee OARandomised parallel assignment; open label3012 monthsCulture-expanded MSCs (10 million or 100 million cells) and hyaluronic acid (HyalOne®) vs. HyalOne®Intra-articular injectionPain and function (VAS, WOMAC, KOOS, EuroQol, SF-16, Lequesne), radiographicOn-going\
(estimated study completion date; February 2015)NCT02123368Intra-Articular Autologous Bone Marrow Mesenchymal Stem Cells Transplantation to Treat Mild to Moderate OsteoarthritisBone marrowMalaysiaIIMild to moderate OA based on Kellgren-Lawrence radiographic classificationRandomised parallel assignment; open label5012 monthsMSCs (fresh or culture-expanded unspecified) in hyaluronic acid "Orthovisc" vs. hyaluronic acidIntra-articular implantationChanges in cartilage thickness (MRI)Unknown (estimated study completion date; March 2014)NCT01459640Treatment of Osteoarthritis by Intra-articular Injection of Bone Marrow Mesenchymal Stem Cells With Platelet Rich Plasma (CMM-PRGF/ART)Bone marrowSpainI/IIKnee OARandomised parallel assignment; open label; multi-centre3812 monthsCulture-expanded MSCs with PRP (PRGF®) vs. PRGF® onlyIntra-articular injectionPain and function (VAS, WOMAC, KOOS, EuroQol, SF-16, Lequesne), radiographicOn-going (estimated study completion date; June 2017)NCT02365142Mesenchymal Stem Cells Enhanced With PRP Versus PRP In OA Knee (MSCPRPOAK)Bone marrowIndiaI/IIKnee OA grade 1--2 Ahlbacks radiographic stagingRandomised parallel assignment double blinded246 monthsCulture-expanded MSCs (10 million cells) with autologous PRP vs. PRP onlyInjected by lateral approachVAS painUnknown\
(estimated study completion date; June 2014)NCT01985633Side Effects of Autologous Mesenchymal Stem Cell Transplantation in Ankle Joint OsteoarthritisBone marrowIranISevere ankle OASingle group assignment open label66 monthsCulture-expanded MSCsIntra-articular injectionSafetyCompleted in September 2011; no publication foundNCT01436058Human Autologous MSCs for the Treatment of Mid to Late Stage Knee OABone marrowCanadaI/IIMid- to late-stage knee OASingle group assignment, open label121 yearCulture-expanded MSCs (1 million, 10 million or 50 million cells)InjectionSafetyOn-going\
(estimated study completion date; February 2021)NCT02351011A Controlled Surveillance of the Osteoarthritic Knee Microenvironment With Regenexx® SD TreatmentBone marrowUSANAKnee OA Kellgren-Lawrence grade 2 or greaterObservational cohort study206 weeksRegenexx® SD (bone marrow concentrate)InjectionTemporal median change in protein concentration or percentage of cellular subpopulationsOn-going\
(estimated study completion date; March 2016)NCT02370823The Effect of Platelet-rich Plasma in Patients With Osteoarthritis of the KneeBone marrowIranIIIKnee OA grade 2 and above (radiographic)Randomised, parallel assignment, placebo controlled, double blinded502 yearBone marrow aspirate vs. placebo (saline)Intra-articular injectionVAS pain, WOMAC physical activity, cartilage repair (MRI)Completed in April 2014; no publication foundNCT02582489Outcomes Data of Bone Marrow Stem Cells to Treat Hip and Knee OsteoarthritisBone marrowUSANAHip and knee OAObservational cohort study121 yearBone marrow concentrateInjectionVAS pain, Harris Hip Score or Knee Society Score, Physician Global AssessmentCompleted in March 2014; no publication foundNCT01601951Use of Autologous Bone Marrow Aspirate Concentrate in Painful Knee Osteoarthritis (BMAC)Bone marrowUSAIIBilateral knee OA Kellgren-Lawrence grade 1--3Randomised, parallel assignment, placebo controlled, single blinded2512 monthsBone marrow concentrate vs. placebo (saline)InjectionSafetyOn-going\
(estimated study completion date; December 2016)NCT01931007Autologous Stem Cells in OsteoarthritisBone marrowMexicoIKnee OA Kellgren-Lawrence radiographic scale grade 2--3Randomised parallel assignment, open label616 monthsHematopoietic stem cells (fresh) vs. acetaminophen (750 mg orally TID)InfusionSafetyCompleted in May 2014; no publication foundNCT01485198The Use of Autologous Bone Marrow Mesenchymal Stem Cells in the Treatment of Articular Cartilage DefectsBone marrowEgyptNot givenAn isolated osteochondral defect with no more than grade 1 or 2 OuterbridgeSingle group assignment, open label2512 monthsCulture-expanded MSCsOpen surgery or arthroscopyClinical scores and radiological imagesUnknown\
(estimated study completion date; December 2014)NCT00891501Autologous Transplantation of Mesenchymal Stem Cells (MSCs) and Scaffold in Full-thickness Articular CartilageBone marrowIranIFull-thickness chondral defectsSingle group assignment, open label612 monthsCulture-expanded MSCs mixed with collagen I scaffoldUnspecifiedKnee cartilage defectsCompleted in December 2010; no publication foundNCT00850187"One-step" Bone Marrow Mononuclear Cell Transplantation in Talar Osteochondral Lesions (BMDC)Bone marrowUSAIIIICRS grade 3--4 Osteochondral lesions of the talar domeSingle group assignment, open label14024 monthsBone marrow concentrateArthroscopyAmerican Orthopaedic Foot and Ankle Society hindfoot scoreOn-going (estimated completion date; June 2016)NCT02005861Transplantation of Bone Marrow Stem Cells Stimulated by Proteins Scaffold to Heal Defects Articular Cartilage of the KneeBone marrowFrance0Knee OA ICRS classification grade 4Single group assignment, open label501 yearFreshly isolated bone marrow mononuclear cells mixed with protein scaffoldArthroscopy (one step procedure)IKSUnknown\
(estimated completion date; December 2014))NCT01159899INSTRUCT for Repair of Knee Cartilage DefectsBone marrowThe NetherlandsNot givenKnee articular cartilage defectSingle group assignment, open label; multi-centre401 yearINSTRUCT scaffold (biodegradable scaffold seeded with autologous primary chondrocytes and bone marrow cells)ArthrotomySafety and lesion fillingCompleted in June 2014; no publication foundNCT01041885HyaloFAST Trial for Repair of Articular Cartilage in the Knee (FastTRACK)Bone marrowHungaryNot givenKnee articular cartilage defectRandomised, parallel assignment, placebo controlled, single blinded, multi-centre2002 yearsHyalofast® scaffold with bone marrow aspirate concentrate vs. microfractureOne-step arthroscopic procedureChanges in KOOSOn-going (estimated study completion date; June 2020)NCT02659215Autologous Adipose Stem Cells and Platelet Rich Plasma Therapy for Patients With Knee OsteoarthritisAdiposeVietnamI/IIIdiopathic or secondary knee OA grade 2--3 radiographic severitynon-randomised unblinded1612 monthsStromal vascular fraction (10--50 million cells) and platelet rich plasma (PRP)InjectionSafetyCompleted in December 2015; no publication foundNCT02142842Effectiveness and Safety of Autologous ADRC for Treatment of Degenerative Damage of Knee Articular CartilageAdiposeRussiaI/IIKnee OA (degenerative damage of knee articular cartilage)Single group assignment, open label1224 weeksAdipose-derived regenerative cells (ADRC) extracted using Celution 800/CRS System (Cytori Therapeutics, Inc.)Intra-articular injectionSafetyOn-going (estimated study completion date; December 2016)NCT02219113Autologous Adipose-Derived Stromal Cells Delivered Intra-articularly in Patients With OsteoarthritisAdiposeUSAI/IIOASingle group assignment, open label, multi-centre5006 monthsMSCs in PRPIntra-articular injectionPain score, functional rating index, visual analogue scale (VAS), physical therapy (PT) and range of motion (53), quality of life scores, reduction in analgesics, adverse eventsOn-going (estimated study completion date; December 2016)NCT01739504Mesenchymal Stem Cell Treatment for Primary Osteoarthritis KneeAdiposeTaiwanIBilateral primary OA Kellgren and Lawrence grade 2--3 as determined by X-raySingle group assignment, open label,1012 monthsMSCs (8--10 million cells)Intra-articular injectionsSafetyOn-going (estimated study completion date; December 2016)NCT02544802Autologous Adipose Tissue-Derived Mesenchymal Progenitor Cells Therapy for Patients With Knee OsteoarthritisAdiposeChinaIIKnee OASingle group assignment, double blinded486 monthsFresh MSCs (10 million, 20 million, 50 million cells twice) vs. placebo (PBS)Intra-articular injectionWOMAC scoreCompleted in December 2013; no publication foundNCT01809769Clinical Trial of Autologous Adipose Tissue-Derived Mesenchymal Progenitor Cells (MPCs) Therapy for Knee OsteoarthritisAdiposeChinaIIKnee OARandomised, parallel assignment, placebo controlled, single blinded4812 monthsCulture-expanded MSCs vs. sodium hyaluronateIntra-articular injectionWOMACOn-going (estimated study completion date; July 2016)NCT02162693Outcomes Data of Adipose Stem Cells to Treat OsteoarthritisAdiposeUSANAKnee OAObservational cohort study5012 monthsCellular concentrateUnknownKOOS, HOOSOn-going (estimated study completion date; September 2017)NCT02241408Clinical Trial to Evaluate Efficacy and Safety of JOINTSTEM in Patients With Degenerative ArthritisAdiposeKoreaII/IIIKnee OARandomised parallel assignment, double blinded12024 weeksMSCs (100 million cells) vs. sodium chlorideInjectionWOMACOn-going (estimated study completion date; July 2017)NCT02658344ADIPOA--Clinical StudyAdiposeFranceIModerate or severe knee OANon-randomised parallel assignment, open label121 yearMSCs (2 million, 10 million, 50 million cells)Intra-articular injectionSafetyCompleted in December 2014; no publication foundNCT01585857Safety and Clinical Effectiveness of A3 SVF in OsteoarthritisAdiposeUSANot givenOASingle group assignment, open label301 yearStromal vascular fraction with activated plateletInjectionPain and inflammation--WOMAC scores, comprehensive inflammation blood panelOn-going\
(estimated study completion date; September 2015)NCT01947348Safety and Clinical Outcomes Study: SVF Deployment for Orthopaedic, Neurologic, Urologic, and Cardio-pulmonary ConditionsAdiposeUSANot givenNeurodegenerative diseases, OA, erectile dysfunction, autoimmune diseases, cardiomyopathies or emphysemaSingle group assignment, open label300036 monthsStromal vascular fractionIntra-venous, intra-articular, and soft tissue injectionSafetyOn-going\
(estimated study completion date; March 2018)NCT01953523Microfracture Versus Adipose-Derived Stem Cells for the Treatment of Articular Cartilage DefectsAdiposeUSANot givenKnee OARandomised, parallel assignment, double blind9024 monthsFibrin glue + acellular collagen dermal matrix + DSCs, + additional layer of fibrin glue vs. microfractureArthroscopyKOOSOn-going (estimated study completion date; December 2020)NCT02090140Autologous Mesenchymal Stem Cells vs. Chondrocytes for the Repair of Chondral Knee Defects (ASCROD)AdiposeSpainI/IIArticular cartilage lesion of the femoral condyleRandomised, parallel assignment, open label3018 monthsCultured stem cells vs. cultured autologous chondrocytesUnknownHyaline cartilage production for chondral knee lesions repairUnknown (estimated study completion date; June 2012)NCT01399749A Phase 2 Study to Evaluate the Efficacy and Safety of JointStem in Treatment of OsteoarthritisAdiposeUSAIIKnee OARandomised, parallel assignment, double blinded456 monthsJoint stem adipose-derived (MSCs) vs. Synvisc-One (hyaluronic acid)Cartilage volume, cartilage articular surface area, cartilage thickness, subchondral bone surface curvature (MRI)On-going (estimated study completion date; September 2017)NCT02674399Allogenic cellsTreatment of Knee Osteoarthritis With Allogenic Mesenchymal Stem Cells (MSV_allo)Bone marrowSpainI/IIKnee OA grade 2--4 of Kellgren and LawrenceRandomised, parallel assignment, double blinded301 yearsCulture-expanded MSCs (40 million cells) vs. hyaluronic acidIntra-articular transplantationSafetyCompleted in June 2014; published in August 2015NCT01586312\
(Linked to study NCT01183728)Clinical Trial of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells Therapy for Knee OsteoarthritisAdiposeChinaIDegenerative arthritis by radiographic criteria of Kellgren LawrenceRandomised, parallel assignment, double blind1848 weeks10 million MSCs vs. 20 million MSCsIntra-articular injectionWOMACOn-going (estimated study completion date; July 2017)NCT02641860Clinical Study of Umbilical Cord Tissue Mesenchymal Stem Cells (UC-MSC) for Treatment of OsteoarthritisUmbilical CordPanamaI/IIModified Kellgren-Lawrence classification grade 2--4 radiographic OA severity.Randomised, parallel assignment, open label4012 monthsSingle intra-articular injection of MSCs vs.\
IV injections of MSC for 3 daysIntra-articular injection; IVSafetyOn-going (estimated study completion date; March 2017)NCT02237846Safety and Feasibility Study of Mesenchymal Trophic Factor (MTF) for Treatment of OsteoarthritisUmbilical CordPanamaI/IIModified Kellgren-Lawrence classification grade 2--4 radiographic OA severity.Non-Randomised, single group assignment,\
open label4012 monthsIntra-articular injection of allogeneic MTF from UC-MSC vs. 12 subcutaneous MTF injections, once per weekIntra-articular injection; subcutaneous injectionSafetyOn-going (estimated study completion date; June 2017)NCT02003131A Study to Assess Safety and Efficacy of Umbilical Cord-derived Mesenchymal Stromal Cells in Knee OsteoarthritisUmbilical CordChileI/IIKellgren-Lawrence classification grade 1--3 radiographic OA severityRandomised, parallel assignment, double blind3012 monthsMSCs (single dose of 20 million MSCs or double dose at 6 month interval) vs. hyaluronic acidIntra-articular injectionSafetyOn-going (estimated study completion date; December 2016)NCT02580695Human Umbilical Cord Mesenchymal Stem Cell Transplantation in Articular Cartilage DefectUmbilical CordChinaIKellgren-Lawrence classification grade 2--4 radiographic OA severitySingle group assignment, open label2012 months20 million cells every month for 4 monthsIntra-articular injectionSafetyOn-going (estimated study completion date; December 2016)NCT02291926Evaluation of Safety and Exploratory Efficacy of CARTISTEM®, a Cell Therapy Product for Articular Cartilage DefectsUmbilical cord bloodKoreaI/IIFocal, full-thickness grade 3--4 articular cartilage defectsSingle group assignment, open label1212 monthsCARTISTEM® (cultured UC MSCs mixed with sodium hyaluronate)UnknownSafetyOn-going (estimated study completion date; May 2017)NCT01733186Study to Compare the Efficacy and Safety of Cartistem® and Microfracture in Patients With Knee Articular Cartilage Injury or DefectUmbilical cord bloodKoreaIIIKnee Articular Cartilage Injury or DefectRandomised, parallel assignment, open label10448 weeksCARTISTEM® (cultured UC MSCs mixed with sodium hyaluronate) vs. MicrofractureSurgeryCRS cartilage repair assessmentCompleted in January 2011; no publication foundNCT01041001Follow-Up Study of CARTISTEM® vs. Microfracture for the Treatment of Knee Articular Cartilage Injury or DefectUmbilical cord bloodKoreaIIIKnee articular cartilage injury or defectRandomised, parallel assignment, open label10360 monthsCARTISTEM® (cultured UC MSCs mixed with sodium hyaluronate) vs. microfractureUnknownIKDC, VAS pain, WOMACOn-going (estimated study completion date; May 2015)NCT01626677Injections of FloGraft Therapy, Autologous Stem Cells, or Platelet Rich Plasma for the Treatment of Degenerative Joint PainAmniotic fluidUSANAPain associated with one of the following conditions: lumbar facet degeneration, degenerative condition causing upper extremity joint pain or degenerative condition causing lower extremity joint painCohort observational study30024 weeksFloGraft^TM^ (allogenic amniotic fluid-derived allograft) vs. autologous BMMSCs vs. platelet rich plasmaInjectionPainOn-going (estimated study completion date; June 2016)NCT01978639IMPACT: Safety and Feasibility of a Single-stage Procedure for Focal Cartilage Lesions of the KneeUnspecifiedThe NetherlandsI/IIFull-thickness articular cartilage lesion on the femoral condyle or trochleaSingle-group assignment, open label3518 monthsAutologous chondrons (chondrocytes with their pericellular matrix) and allogeneic MSCs in the fibrin glue carrierUnspecified (single stage surgery)SafetyOn-going (Estimated Study Completion Date: August 2015)NCT02037204Allogeneic Mesenchymal Stem Cells in OsteoarthritisUnspecifiedIndiaIIKellgren and Lawrence classification grade 2--3 radiographic OA severityRandomised, double blind, multi-centre602 yearsCulture-expanded MSCs in 2 ml plasmalyte + 2 ml, hyaluronan vs. 2 ml, plasmalyte + 2 ml, hyaluronanIntra-articularSafety and tolerabilityUnknown (estimated study completion date; July 2014NCT01453738Allogeneic Mesenchymal Stem Cells for OsteoarthritisUnspecifiedMalaysiaIIKellgren and Lawrence classification grade 2--3 OARandomised, double blind, multi-centre721 yearCulture-expanded MSCs in 2 ml plasmalyte + 2 ml, hyaluronan vs. 2 ml, plasmalyte + 2 ml, hyaluronanIntra-articularSafety and tolerabilityUnknown (estimated study completion date; February 2013)NCT01448434Autologous or allogenic unspecifiedTransplantation of Bone Marrow Derived Mesenchymal Stem Cells in Affected Knee Osteoarthritis by Rheumatoid ArthritisBone marrowII/IIIIranRheumatoid arthritisRandomised, parallel assignment, open label606 monthsMSCs vs. salineIntra-articular injectionPainCompleted in December 2011; no publication foundNCT01873625Safety and Efficacy Study of MSB-CAR001 in Subjects 6 Weeks Post an Anterior Cruciate Ligament ReconstructionUnknownI/IIAustraliaAnterior cruciate ligament injuryRandomised, parallel assignment, double blind242 yearMSB-CAR001 (a preparation of MSCs) with hyaluronan vs. hyaluronan aloneInjectionSafetyUnknownNCT01088191

#### Defects {#FPar14}

The majority of studies (42%) used MSCs to treat knee osteoarthritis \[[@CR103]--[@CR115]\]. The rest of the studies looked at knee cartilage defects except for two which studied the ankle talar dome \[[@CR116], [@CR117]\]. One study used MSCs to treat knee osteoarthritis (OA), knee OA and ankle OA \[[@CR112]\].

Of the knee cartilage defects, the patients were heterogeneous with varying defect sizes and locations, including the patellae \[[@CR118]--[@CR121]\], patella-femoral joints \[[@CR122], [@CR123]\], femoral condyle \[[@CR113], [@CR119]--[@CR121], [@CR123]--[@CR132]\], trochlear \[[@CR119]--[@CR121]\] and tibial plateau \[[@CR121]\]; and several had multiple defect sites \[[@CR105], [@CR120], [@CR123], [@CR128]\].

#### Previous treatment and associated procedures {#FPar15}

The majority of patients who received MSC treatment had undergone previous arthroscopy \[[@CR103], [@CR104], [@CR118], [@CR119], [@CR122], [@CR124], [@CR130]\], failed debridement \[[@CR113], [@CR118], [@CR119], [@CR121]--[@CR123], [@CR125], [@CR127], [@CR131]\] or bone marrow stimulation \[[@CR114], [@CR116], [@CR117], [@CR126]\].

#### Cell harvest source {#FPar16}

Twenty-one studies (68%) used bone marrow-derived MSCs from the anterior or posterior superior iliac spine \[[@CR103]--[@CR105], [@CR109], [@CR111]--[@CR113], [@CR115]--[@CR118], [@CR120], [@CR122]--[@CR128], [@CR130]--[@CR132]\]. Five studies (18%) used adipose-derived MSCs \[[@CR106]--[@CR108], [@CR110], [@CR114]\], two studies (7%) used synovium-derived MSCs \[[@CR129], [@CR133]\] and two studies (7%) used peripheral blood progenitor cells collected by apheresis \[[@CR119], [@CR121]\].

#### Cell stage {#FPar17}

Twenty studies (61%) culture-expanded their cells \[[@CR103]--[@CR105], [@CR107]--[@CR113], [@CR115], [@CR118], [@CR120], [@CR122]--[@CR126], [@CR129], [@CR133]\], whereas 11 studies (39%) used fresh concentrated stem cells from bone marrow \[[@CR116], [@CR117], [@CR127], [@CR128], [@CR130]--[@CR132]\], fat tissues \[[@CR106], [@CR114]\] or peripheral blood \[[@CR119], [@CR121]\] in a one stage-procedure. In studies using bone marrow concentrate, approximately 60 ml of bone marrow aspirate was harvested and concentrated down to a volume of 2--4 ml before use \[[@CR116], [@CR117], [@CR127], [@CR130]--[@CR132]\]. In studies using culture-expanded cells, the majority used cells from early passages, P1--P3 \[[@CR103], [@CR105], [@CR109], [@CR110], [@CR112], [@CR113], [@CR115], [@CR118], [@CR120], [@CR122]--[@CR125], [@CR129]\]. One study reported the use of cells at a late passage (P5) \[[@CR104]\] ,and five studies did not specify a passage number \[[@CR107], [@CR108], [@CR111], [@CR126], [@CR133]\].

Thirteen studies (42%) confirmed the phenotype of cells before clinical application \[[@CR105], [@CR108]--[@CR110], [@CR112], [@CR115], [@CR119], [@CR120], [@CR122]--[@CR125], [@CR129]\]. Commonly used surface markers to select MSCs were CD29, CD44, CD73, CD90 and CD105. Also CD14, CD34 and HLA-DR were used to eliminate non-MSCs.

#### Cell dose and delivery {#FPar18}

The number of cells applied (dose) varied from 2--57 million for bone marrow-derived MSCs \[[@CR103]--[@CR105], [@CR109], [@CR111]--[@CR113], [@CR118], [@CR120], [@CR122]--[@CR125], [@CR129]\] and from 1.2--100 million for adipose-derived MSCs \[[@CR107], [@CR108], [@CR110], [@CR114]\]. For synovial MSCs, 8--77 million cells were used \[[@CR129], [@CR133]\], and for peripheral blood progenitor cells, 20 million cells were used \[[@CR119]\]. Also, the methods for implantation varied from arthroscopic implantation (35%) \[[@CR107], [@CR108], [@CR116], [@CR117], [@CR127], [@CR128], [@CR130]--[@CR133]\], intra-articular injection \[[@CR103]--[@CR106], [@CR109]--[@CR112], [@CR114], [@CR115], [@CR119], [@CR121], [@CR123]\] or open surgery (29%) \[[@CR113], [@CR118], [@CR120], [@CR122]--[@CR126], [@CR129]\].

In the cell therapy studies, the cells were suspended with a variety of different co-stimulators, including hydroxyapatite (HA) \[[@CR106], [@CR119], [@CR121], [@CR123]\], platelet rich plasma (PRP) \[[@CR106], [@CR114]\] and platelet lysate \[[@CR104]\]. Some studies also administered multiple injections of stem cells \[[@CR119], [@CR121]\] and/or further injection of HA \[[@CR115], [@CR119], [@CR121], [@CR123]\], PRP \[[@CR106], [@CR114]\] or nucleated cells \[[@CR104]\] following a stem cell injection.

The most frequently used scaffolds were type I collagen of porcine or bovine origin \[[@CR113], [@CR118], [@CR122], [@CR124], [@CR126], [@CR129]\], followed by ascorbic acid sheet \[[@CR120], [@CR123]\] and platelet-rich fibrin glue mixture \[[@CR108], [@CR125]\].

#### Rehabilitation {#FPar19}

Early continuous passive motion was employed in 14 studies \[[@CR113], [@CR117]--[@CR122], [@CR124]--[@CR127], [@CR129]--[@CR131]\]. Six studies did not report details on post-operation rehabilitation \[[@CR104]--[@CR106], [@CR109], [@CR116], [@CR132]\]. Three studies aimed for full weight bearing very early by week 4 \[[@CR107], [@CR108], [@CR122]\] whereas 11 studies (40%) aimed for full weight bearing by the 6th--8th week \[[@CR113], [@CR117]--[@CR121], [@CR124], [@CR125], [@CR127], [@CR131], [@CR133]\]. No study addressed the effect of rehabilitation on the quality of the repair.

#### Outcomes {#FPar20}

Most commonly used outcome measures for treatment efficacy were radiological (77%) \[[@CR103]--[@CR106], [@CR109]--[@CR112], [@CR115]--[@CR117], [@CR119], [@CR121], [@CR123]--[@CR125], [@CR127]--[@CR134]\] and arthroscopic assessment (61%) \[[@CR107], [@CR108], [@CR113], [@CR116]--[@CR122], [@CR124]--[@CR126], [@CR130]--[@CR133]\]. Most commonly used patient-reported outcomes are International Knee Documentation Committee (IKDC) score (36%), followed by a visual analogue scale (VAS) pain (39%) and Tegner activity scale (29%).

#### Adverse effects {#FPar21}

None of the studies reported any severe adverse effects related to the MSC treatment. Two group reported minor adverse events including mild pain and effusion after the injections, which persisted for no more than 7 days \[[@CR103], [@CR114]\].

Conclusions {#Sec8}
===========

There is a growing fascination with the role of mesenchymal stem cells in cartilage repair.

As early as the 1950s, Pridie showed fibrocartilaginous repair through subchondral drilling \[[@CR135]--[@CR137]\]. Initially, Pridie drilling was reported as a treatment for osteoarthritis \[[@CR135], [@CR138]\] and was often associated with many additional procedures such as synovectomy and trimming of osteophytes.

Since Pridie's initial experiments, the process of marrow stimulation techniques or exposure of mesenchymal stem cells from cancellous bone has changed its guise on several occasions.

Ficat in 1979 described "Spongialization" in which the cancellous bed was exposed in 85 patients with chondral lesions of the patella with encouraging results \[[@CR139]\]. Johnson et al. \[[@CR140]\] described abrasion arthroplasty and encouraged its use especially in younger patients \[[@CR141], [@CR142]\]. Other authors had less positive outcomes \[[@CR143]--[@CR146]\]. Dandy wrote an entertaining article on abrasion arthroplasty where he highlighted that at least in the treatment of osteoarthritis, its effects could relate to the arthroscopic washout, rest or even the placebo effects of the charismatic surgeon \[[@CR147]\]. The final evolution of marrow stimulation was the term "Microfracture" enabled by commercially manufactured bone picks used to breach the subchondral bone \[[@CR8]\]. Marrow-stimulating technique procedures, in particular microfracture, are now considered the first-line treatment for full-thickness cartilage lesions and have demonstrated good to excellent results in 60--80% of patients \[[@CR148], [@CR149]\].

Cartilage repair has evolved from marrow stimulation techniques through to chondrocyte transplant and now stem cells at rapid pace. An ideal translational pipeline would demonstrate how in vitro data was used to inform a pre-clinical model, which would later form a phase I/IIa first-in-man study and subsequently a phase III clinical trial. This would of course be the safe and responsible method by which novel therapies are brought to the market.

This systematic review is the first of its kind to explore the full spectrum of evidence from in vitro studies, through animal studies to human clinical trials, and yet, we found little evidence of connectivity between in vitro, animal and then human work. In fact, we did not find a single group that had carried out and reported studies in all three categories.

Indeed, even from groups, which showed a seemingly hierarchical approach to translation, discrepancies became apparent. For example, Saw et al. from Korea used a pre-clinical goat model to repair cartilage defects using HA plus bone marrow-derived cells \[[@CR150]\] and then moved into a first-in-man study, but in doing so, elected to change from bone marrow aspirate to peripheral blood and justified this change because it was easier to harvest peripheral blood than marrow \[[@CR151]\].

There are several sources of cells that have been used in cartilage repair including bone marrow, peripheral blood, synovium, adipose tissue and umbilicus (Table [14](#Tab14){ref-type="table"}) without any clear evidence of superiority of one over the other.

One stage vs. two stages {#Sec9}
------------------------

As two stage procedures involving cell culture are expensive and cumbersome, there is an increasing push towards a single stage stem cell treatment. In this situation there is some supportive pre-clinical data \[[@CR91], [@CR95], [@CR98], [@CR152]--[@CR154]\], but there does not appear to be a pre-clinical study that directly compares bone marrow concentrates against cultured MSCs.

Several groups have reported the use of bone marrow concentrates in clinical practice \[[@CR116], [@CR117], [@CR127], [@CR128], [@CR130]--[@CR132]\], in which the buffy coat is used containing the nucleated cells, of which a few will be stem cells.

Briefly, the patient has approximately 60 mL of bone marrow harvested from the iliac crest which is then spun down in a cell centrifuge (SmartPrep, Harvest Technologies Corp., USA, or IOR-G1, Novagenit, Mezzolombardo, TN, Italy) to provide 6 mL of concentrate containing nucleated cells. A small amount of the nucleated cells are then placed onto a hyaluronic acid membrane (Hyalofast, Fidia Advanced Biopolymers, Italy) or collagen membrane (IOR-G1, Novagenit, Mezzolombardo, TN, Italy) as a scaffold, which is then arthroscopically placed into the cartilage defect which had been pre-prepared using a burr or drill. The construct is then held with a platelet gel obtained from a harvest of 120 mL of patient's venous blood taken the day before surgery (Vivostat system, (Vivolution, Denmark)) \[[@CR118]\]. The results of the first 30 patients have been reported as showing improvements in MRI and arthroscopic appearance as well as clinical scores at 3 years follow-up \[[@CR118]\].

This new technique is of course an evolution of the autologous matrix-enhanced chondrogenesis (AMIC) which used the stem cells from the adjacent marrow (and not pre-harvested bone marrow concentrates) within either collagen patches \[[@CR155]--[@CR157]\] or polyglycolic acid--hyaluronan-based scaffolds \[[@CR158], [@CR159]\].

There has also been a further step taken to avoid bone marrow harvest in which peripheral blood has been used in knee chondral lesions. In an RCT, arthroscopic subchondral drilling was followed by postoperative intra-articular injections of hyaluronic acid (HA) with and without peripheral blood stem cells (PBSC). Fifty patients were studied and randomised 1 week after surgery to receive either 8 injections of HA or 8 injections of HA plus PBSC. Those that underwent PBSC received stimulation with filgrastim, which contains recombinant human granulocyte colony-stimulating factor prior to harvest \[[@CR106], [@CR151]\]. At 18 month follow-up, they reported no adverse effects and improved MRI findings in the PBSC group compared to HA alone, took biopsies of 16 of the 25 patients in each group and claimed better tissue morphology in the PBSC group, as graded by the International Cartilage Repair Society Visual Assessment Scale II. Interestingly, however, the same group's pre-clinical used bone marrow aspirates and not peripheral blood \[[@CR150]\].

Autologous vs. allogenic {#Sec10}
------------------------

There is an increasing interest in allogenic cells to avoid donor site morbidity and to reduce cost. The pre-clinical data with regards to allogenic cells is conflicting. One group showed promising results of allogenic MSCs in a rabbit model when compared to autologous cells, although numbers were small \[[@CR160], [@CR161]\]. Another group compared autologous chondroprogenitor cells and allogenic chondroprogenitor cells against controls in an equine model and reported inferior repair in the allogenic cell group \[[@CR23]\]. Despite conflicting pre-clinical data, human studies using allogenic cells began in Korea in 2009. A phase I/IIa study to assess safety and efficacy of a combination of human umbilical cord blood-derived mesenchymal stem cells and sodium hyaluronate (CARTISTEM^®^ (MEDIPOST Co., Ltd., Korea)) was performed in knee chondral defects (NCT01041001). A parallel phase 3, open-label, multi-centre RCT comparing CARTISTEM^®^ and microfracture in knee chondral defects was carried out in Korea and the USA (NCT01733186). Results are still pending.

Another area of huge controversy is the actual dose of cells that should be used. In vitro between 50,000 cells/mL and 100 billion cells/ml have been studied. In pre-clinical animal studies, this ranged from 1000 to 1 billion cells/mL, and in human studies, the reported range has been 1.2 million cells/mL--24 million cells/mL.

It remains unclear what the most appropriate cell dose should be, with some groups reporting that a higher cell number leads to a better repair \[[@CR52], [@CR71], [@CR87], [@CR95], [@CR162]--[@CR164]\], but Zhao et al. \[[@CR99]\] highlighted the limitation to cell saturation and survival, and thus, there may be a top limit to cell number that can be used to aid repair.

A multitude of methods for cell delivery have also been adopted, from direct joint injection or embedded in a plethora of scaffolds, such as type I collagen gels of porcine or bovine origin, ascorbic acid sheets or fibrin glues (Table [14](#Tab14){ref-type="table"}).

In vitro and in pre-clinical studies, a plethora of growth factors have been studied including TGF-β1 and TGF-β2 and BMP-7 but none of these have been included in human clinical trials (Table [5](#Tab5){ref-type="table"}).

It is clear that the relationship between cell passage, cell dose, the use of scaffolds and growth factors and the efficacy of MSC treatment is still to be established.

Future {#Sec11}
------

There is no question that the field of cartilage repair accelerates at rapid pace, and it is clear that the single stage procedures are likely to win over two stage procedures to save costs and reduce the burden on both provider and the patient. The reduction of donor site morbidity is a further driver helping direct progress.

The concept of cell banks of allogenic cells clearly meets all of the above criteria, but the lack of good supporting pre-clinical and long-term safety and efficacy data does little to pacify potential pitfalls of this direction. The fact that the phase 3 RCT of allogenic umbilical stem cells was allowed to be registered (NCT01041001) before the same group registered their phase I/IIa safety study (NCT01733186) intimates that sometimes clinical pace exceeds that of the regulators to lay down new ground.

Tools are likely to be introduced to the operating theatre that might improve the efficacy of treatment, such as fluorescence-activated cell sorting (FACS) machines which can isolate MSCs from the buffy coat of bone marrow aspirate by their cell surface markers. At present, this technology is expensive and complicated and ways to reduce cost and make the process simple are required before they could enter the operating theatre.

Induced pluripotent stem cells (iPSCs) are adult somatic cells that have been genetically reprogrammed to an embryonic stem cell-like state by being forced to express genes and factors important for maintaining the defining properties of embryonic stem cells \[[@CR165]\].

These cells show unlimited self-renewal, and some in vitro studies have shown chondrogenic differentiation by iPSCs from human chondrocytes biopsied from osteoarthritic knees \[[@CR166]\] and cartilage formation from human neural stem cells \[[@CR167]\]. However, this work is at a very early stage, and aside from the ethical considerations, much research into control of cell phenotype and cell fate to alleviate concerns for cancer risk are required before this technology is ready to move into the pre-clinical and clinical realms.

In conclusion, this review is a comprehensive assessment of the evidence base to date behind the translation of basic science to the clinical practice of cartilage repair. We have revealed a lack of connectivity between the in vitro, pre-clinical and human data and a patchwork quilt of synergistic evidence. It appears that the drivers for progress in this space are largely driven by patient demand, surgeon inquisition, and a regulatory framework that is learning at the same pace as new developments take place. We strongly recommend funding body commission studies that have a clear translational purpose in order to drive the science towards patient benefit.
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:   Induced pluripotent stem cells
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:   Medical Subject Headings
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:   Real-time polymerase chain reaction
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:   Western Ontario and McMaster Universities Arthritis Index

None

Funding {#FPar22}
=======

There was no external funding for this work.

Availability of data and materials {#FPar23}
==================================

Not applicable

Authors' contributions {#FPar24}
======================

All authors were involved in the conception and design of the study or acquisition of the data or analysis and interpretation of the data and contributed to drafting the article or revising it critically for important intellectual content. All authors read and approved the final manuscript.

Competing interests {#FPar25}
===================

The authors declare that they have no competing interests.

Consent for publication {#FPar26}
=======================

Not applicable

Ethics approval and consent to participate {#FPar27}
==========================================

Not applicable
